A new partnership between two powerhouses in the pharmaceutical industry promises substantial advancements in drug discovery and development. Novartis, one of the largest pharmaceutical companies globally, will pay Schrödinger $150 million upfront to utilize its advanced computing tools and
Insilico Medicine, an AI-based drug developer, has made significant strides with its lead candidate, ISM001-055, in the treatment of idiopathic pulmonary fibrosis (IPF). Following promising results from a Phase IIa trial, the company is now gearing up for potentially pivotal clinical trials that
The field of regenerative medicine has seen remarkable advancements over the past few decades, with stem cell therapies emerging as a promising frontier. These therapies hold the potential to revolutionize the treatment of a wide array of diseases and conditions by harnessing the body's own repair
Imagine a common over-the-counter pain reliever having the potential to alleviate the symptoms of a rare genetic disorder that currently lacks any formal treatment. This possibility could mark a significant breakthrough for patients who face enormous challenges and discomfort due to their
Advancements in cancer diagnosis and treatment have significantly improved survival rates, leading to a growing number of young cancer survivors. This demographic shift brings unique challenges as these individuals navigate life post-treatment, facing physical, emotional, and social upheavals. The
In a strategic move aimed at ensuring the utmost safety and efficacy, the US Food and Drug Administration (FDA) has recently announced a three-month delay in the priority review of Neurotech Pharmaceuticals' NT-501 eye cell therapy implant. This extension shifts the anticipated action date to March
